Galecto Biotech AB
10
1
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.0%
2 terminated/withdrawn out of 10 trials
66.7%
-19.9% vs industry average
0%
0 trials in Phase 3/4
75%
3 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Role: lead
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Role: collaborator
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Role: lead
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Role: lead
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
Role: lead
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
Role: lead
A Study to Compare Pharmacokinetics of GB1211
Role: lead
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
Role: lead
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
Role: lead
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Role: lead
All 10 trials loaded